A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/09/2006	WO2006116848A1 Substituted butyrophenone derivatives
11/09/2006	WO2006116815A1 Composition for the control of cholesterol levels
11/09/2006	WO2006116814A1 Composition and uses thereof
11/09/2006	WO2006102029A3 Methods and compositions for the treatment of urinary incontinence
11/09/2006	WO2006100413A3 Novel compounds derived from 5-thioxylose and therapeutic use thereof
11/09/2006	WO2006099943A8 Amide-substituted 8-n-benzimidazoles, method for the production thereof, and use of the same as medicaments
11/09/2006	WO2006099941A8 Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
11/09/2006	WO2006099940A8 Substituted, bicyclic 8-pyrrolidino-benzimidazoles, method for their production and their use as medicaments
11/09/2006	WO2006097555A3 Pain-inhibiting composition for newborns
11/09/2006	WO2006097337A9 11β-HYDROXYSTEROID DEHYDROGENASES
11/09/2006	WO2006096778A3 Polyphenol coxib combinations and methods
11/09/2006	WO2006094704A3 Natural ligand of g protein coupled receptor rcc356 and uses thereof
11/09/2006	WO2006088676A3 Method of modulating drug release from a coated substrate
11/09/2006	WO2006086613A3 2-METHYLENE-19-NOR- (20S-24S) - 1α, 25-D IHYDROXYVITAMIN-D2
11/09/2006	WO2006083947A3 Compositions and methods for treating fibrotic disorders
11/09/2006	WO2006079015A3 Quorum sensing modulators
11/09/2006	WO2006078984A3 Uses of methylphenidate derivatives
11/09/2006	WO2006078457A3 Use of resolvins to treat gastrointestinal diseases
11/09/2006	WO2006077501A3 Decladinosyl-macrolides with anti-inflammatory activity
11/09/2006	WO2006074293A3 Bicyclic dihydropyrimidines as eg5 inhibitors
11/09/2006	WO2006074051A3 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
11/09/2006	WO2006072828A3 Heteroaromatic quinoline compounds and their use as pde10 inhibitors
11/09/2006	WO2006069241A3 Methods for promoting oral health in animals
11/09/2006	WO2006063033A3 Aryl amide sphingosine 1-phosphate analogs
11/09/2006	WO2006053315A3 Methods and compositions for treating cellular proliferative diseases
11/09/2006	WO2006053159A3 Medical device for delivering biologically active material
11/09/2006	WO2006048336B1 Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents
11/09/2006	WO2006048242A3 Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
11/09/2006	WO2006042007A3 Chromenone compounds as calcilytics
11/09/2006	WO2006041921A3 Preparation and uses of rhodanine derivatives
11/09/2006	WO2006040181A3 4-phenylsulfonamidopiperidines as calcium channel blockers
11/09/2006	WO2006031491A3 Tricyclic anilide spirolactam cgrp receptor antagonists
11/09/2006	WO2006028963A3 Substituted heterocyclic compounds and uses thereof
11/09/2006	WO2006025978A3 Non-antibiotic intervention of chlamydial infection
11/09/2006	WO2006020767A3 Thiazole based inhibitors of atp-utilizing enzymes
11/09/2006	WO2006020137A3 Oligomeric compounds
11/09/2006	WO2006019673A3 Jiadifenin analogs and uses thereof
11/09/2006	WO2006019327B1 Deuterium depleted water (ddw) using as adjuvant in cancer therapy for cytostatics toxicity reduction
11/09/2006	WO2006017650A3 Iron chelators for treating radiocontrast-associated renal dysfunction
11/09/2006	WO2006015191A3 Multicyclic lonidamine analogs
11/09/2006	WO2006014968A3 Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
11/09/2006	WO2006014237A3 Triple anti-irritant composition
11/09/2006	WO2006004941A3 Biomaterial
11/09/2006	WO2006002255A3 A pharmaceutical formulation of balaglitazone
11/09/2006	WO2006000577A3 Lxr agonists to promote bone homeostasis
11/09/2006	WO2006000228B1 Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
11/09/2006	WO2005120524A3 Nutritional formulations
11/09/2006	WO2005120503A3 N-aryl piperidine compounds for inhibiting hiv infection
11/09/2006	WO2005112639A3 Treatment or prevention of respiratory viral infections with immunomodulator compounds
11/09/2006	WO2005099694A8 Combination of a heterocyclic compound and an antioxidant and use thereof for treating obesity
11/09/2006	WO2005097087A3 Merged ion channel modulating compounds and uses thereof
11/09/2006	WO2005089711A3 Pharmaceutical formulation containing unmilled flutamide
11/09/2006	WO2005081866A3 Hemostatic agent for topical and internal use
11/09/2006	WO2005079802A8 Bipyridyl amides as modulators of metabotropic glutamate receptor-5
11/09/2006	WO2005079532A3 Methods and compositions for enhancing risc activity in vitro and in vivo
11/09/2006	WO2005074989A3 Combination of a dna topoisomerase inhibitor and an iap inhibitor
11/09/2006	WO2005074603A3 Aminobenzoxazoles as therapeutic agents
11/09/2006	WO2005055955B1 DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
11/09/2006	WO2005055927A3 Compositions and methods for topical treatment of skin infection
11/09/2006	WO2005048926A3 Methods for treating pain
11/09/2006	US20060253914 Ha4,a new osteoblast-and chondrocyte-specific small secreted peptide, compositions and methods of use
11/09/2006	US20060253100 Systems and Methods to Treat Pain Locally
11/09/2006	US20060252943 Chemical process
11/09/2006	US20060252942 Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one
11/09/2006	US20060252934 For treatment of asthma, allergies, inflammation and anxiety; antihistamines; sedatives; tranquilizing agents
11/09/2006	US20060252930 Fki-1366 substances and process for producing the same
11/09/2006	US20060252839 Cyclopenteneones for antiischemic agents, antiinflammatory agents and aging resistance
11/09/2006	US20060252838 Use of spermine and/or spermidine against skin ageting in dietary, pharmaceuetical or cosmetic compositions
11/09/2006	US20060252837 Diamine derivatives
11/09/2006	US20060252836 Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
11/09/2006	US20060252835 Modafinil polymorphic forms
11/09/2006	US20060252834 Anti-aging skin care; e.g. N-[4-(N-hydroxycarbamoyl)phenyl]benzamide; inhibits collagenase and/or elastase expression; less skin irritation than conventional retinoic acid
11/09/2006	US20060252833 Improve efficiency when administered with conventional drugs; side effect reduction; Parkinson's disease therapy; administering a fatty acid
11/09/2006	US20060252832 Derivatives of acanthoic and kauranoic acid; treatment of cachexia' cardiovascular disease, otitis media, sinusitis and transplant; anti-inflammatory, diabetic and cancer agents
11/09/2006	US20060252831 Method for the treatment of magnesium and potassium deficiencies
11/09/2006	US20060252830 Method for the treatment of magnesium and potassium deficiencies
11/09/2006	US20060252829 Formulations and methods for treating amyloidosis
11/09/2006	US20060252827 Therapeutic use of of acyglycerols and the nitrogen-and sulphur-containing analogues thereof
11/09/2006	US20060252826 Salt of (2s, 3s) -3- [ [ (is) -1- isobutoxymethyl-3-methylbutyl] carbamoly] oxirane-2-carboxylic acid
11/09/2006	US20060252825 Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
11/09/2006	US20060252824 Substance with sedative effect
11/09/2006	US20060252823 Isocoumarin-based inhibitors of urokinase-type plasminogen activator
11/09/2006	US20060252822 Mitochrondrial permeability transition pore affinity labels and modulators
11/09/2006	US20060252821 Ethyl-N-((3S,4R)-3-Hydroxy-2,2-Dimethyl-6-{2-Oxo-2-[4-(pyridin-3-ylmethyl)piperazin-1-yl]ethyl}-3,4-dihydro-2H-Chromen-4-yl)Benzenesulfonamide; treating cardiovascular disease ; potassium channel blocker; chemical intermeidates; antiarrhythmia agent
11/09/2006	US20060252820 Composition for oral administration containing alkylene dioxybenzene derivative
11/09/2006	US20060252819 Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus
11/09/2006	US20060252818 Monoamine re-uptake inhibitors and methods relating thereto
11/09/2006	US20060252817 Treatment and inhibition of disease conditions using flexible heteroarotinoids
11/09/2006	US20060252816 Process for the preparation of atorvastatin and intermediates
11/09/2006	US20060252815 Novel combination of anticholineric and beta mimetics for the treatment of respiratory diseases
11/09/2006	US20060252814 Formulation comprising a betablocker and optionally a cholestrol-lowering agent
11/09/2006	US20060252813 Apparatus for curing a composite laminate
11/09/2006	US20060252812 1'-(2-cyclopropylethyl)spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one; for treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain
11/09/2006	US20060252811 Substituted benzylimidazoles useful for the treatment of inflammatory diseases
11/09/2006	US20060252810 e.g. 5-(4-Fluorophenyl)-4-(4-pyridinyl)imidazole-2-thio-3-propyl-N-phthalimide; immunomodulating and cytokine-release-inhibiting action; antiinflammatory agent
11/09/2006	US20060252809 N-Thiolated 2 Oxazolidone Antibiotics
11/09/2006	US20060252808 Methods for treating nephrolithiasis
11/09/2006	US20060252807 Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
11/09/2006	US20060252806 synergistic use of angiotensin II receptor antagonist like (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazol-5-carboxylate with the calcium channel blockers; calcium channel blockers containing 1,4-dihydropyridine group
11/09/2006	US20060252805 synergistic use of angiotensin II receptor antagonist like (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazol-5-carboxylate with the calcium channel blockers; calcium channel blockers containing 1,4-dihydropyridine group

1 ... 4013 4014 4015 4016 4017 4018 4019 4020 4021 4022 4023 4024 4025 4026 4027 4028 4029 4030 4031 4032 4033 ... 7860